Baxter sees Q4 adjusted EPS 77c-81c, consensus 84c

Sees Q4 revenue down low single digits. The company said, “Given the unprecedented impact of Hurricane Helene on the company’s North Cove operations and related production, Baxter (BAX) is adjusting its full-year 2024 financial outlook to reflect the estimated impact of the hurricane on its fourth-quarter results. As a result of the hurricane, Baxter expects total company fourth-quarter sales to be negatively impacted by approximately $200 million, including an estimated $40 to $50 million impact on Kidney Care sales and approximately $150 to $160 million impact on Medical Products & Therapies sales. Total company adjusted diluted EPS (including discontinued operations) are expected to be negatively impacted by $0.15 to $0.20 per share.”